All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Compatibility of selected active pharmaceutical ingredients with poly(D, L-lactide-co-glycolide): Computational and experimental study

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22340%2F22%3A43924994" target="_blank" >RIV/60461373:22340/22:43924994 - isvavai.cz</a>

  • Result on the web

    <a href="https://www.sciencedirect.com/science/article/pii/S0939641122002089" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0939641122002089</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/j.ejpb.2022.09.013" target="_blank" >10.1016/j.ejpb.2022.09.013</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Compatibility of selected active pharmaceutical ingredients with poly(D, L-lactide-co-glycolide): Computational and experimental study

  • Original language description

    Biodegradable polyesters have emerged as a promising class of polymers for the development of efficient drug delivery systems for various treatments (including cancer treatment) due to their biocompatibility, low toxicity, and controlled drug release. This study presents a computational and experimental evaluation of the compati-bility of selected model active pharmaceutical ingredients (APIs) with poly(D, L-lactide-co-glycolide) (PLGA), which is a key parameter to designing drug delivery systems based on amorphous solid dispersions (ASDs) and polymeric micro-or nanoparticles. PLGA with different molar ratios of the monomer units, i.e., lactide to gly-colide ratio of 50:50 (PLGA50) or 75:25 (PLGA75), were investigated as polymeric carriers for the following model APIs: ibuprofen (IBU), paracetamol (PARA), naproxen (NAP), and indomethacin (IND). The phase dia-grams obtained by a combination of calorimetric measurements and modeling using the perturbed-chain sta-tistical associating fluid theory (PC-SAFT) equation of state (EOS) demonstrated low solubility of the model APIs in the studied copolymers at storage temperature (25 degrees C). The amorphous-amorphous phase separation was predicted by the PC-SAFT EOS for all API-PLGA systems and experimentally detected for the IBU-PLGA50, IBU-PLGA75, and NAP-PLGA75 systems. To investigate the physical stability of the API-PLGA systems and their link to the constructed phase diagrams, API-PLGA75 formulations were prepared using a melting process, and their solid-state properties were monitored over time. Of the analyzed API-PLGA75 formulations, only IND-PLGA75 remained in the amorphous state after 20 weeks of storage under dry conditions at 25 degrees C, while the other formulations recrystallized rapidly after preparation (IBU-PLGA75 and NAP-PLGA75) or after a limited storage period (PARA-PLGA75), reflecting poor compatibility of the investigated APIs with the PLGA copolymers and limited kinetic stabilization, as predicted from the constructed phase diagrams. Another important output of this work is the evaluation of the pure predictions of phase diagrams using the PC-SAFT EOS and its performance in ranking API-polymer compatibility.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10404 - Polymer science

Result continuities

  • Project

    <a href="/en/project/GA22-07164S" target="_blank" >GA22-07164S: Rational design of drug delivery systems based on tailored biodegradable polymers using an iterative in silico and experimental approach</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    European Journal of Pharmaceutics and Biopharmaceutics

  • ISSN

    0939-6411

  • e-ISSN

    1873-3441

  • Volume of the periodical

    179

  • Issue of the periodical within the volume

    říjen 2022

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    14

  • Pages from-to

    232-245

  • UT code for WoS article

    000869794700001

  • EID of the result in the Scopus database

    2-s2.0-85138798869